2022 Pfizer Fellowship Program - in partnership with
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
2022 Pfizer Fellowship Program in partnership with
TABLE OF
CONTENTS
3 Our Purpose 23 North America Medical Affairs (NAMA)/Global
Medical Affairs (GMA) – Inflammation &
4 Diversity & Inclusion Immunology Fellowship Overview
5 Introduction to the Pfizer Fellowship Program 26 U.S. Medical Affairs – Rare Disease
Fellowship Overview
7 Leadership Team Structure 2021–2022
29 Clinical Development Fellowship Overview
9 Our Current Fellows
11 U.S. and Global Medical Affairs – Oncology 30 Risk Management Center of Excellence/U.S.
Fellowship Overview Food and Drug Administration (RMCoE/FDA)
– Risk Management Fellowship Overview
14 Global Medical Information (GMI)/Global
Medical Affairs (GMA), Internal Medicine 32 Internal Medicine, Field Medical Outcomes and
– Fellowship Overview Analytics (IM, Medical O&A) Fellowship Overview
18 North America Medical Affairs (NAMA)/ 34 Alumni Spotlight
Global Medical Affairs (GMA) – Internal
Medicine Fellowship Overview 35 Pfizer Pharmacy Networks
20 North America Medical Affairs (NAMA)/ 36 Rutgers Pharmaceutical Industry
Global Medical Affairs (GMA) – Hospital Fellowship Program
Business Fellowship Overview
2022 PFIZER FELLOWSHIP PROGRAM | 2
OUR PURPOSE
BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES
OUR VALUES AND BEHAVIORS
COURAGE EXCELLENCE EQUITY JOY
THINK BIG FOCUS ON WHAT MATTERS BE INCLUSIVE TAKE PRIDE
We pursue daring ideas – We prioritize what is important – We respect all people for who We celebrate our impact –
because breakthroughs because getting those few things they are – because diversity because our work changes
favor the bold. right can make all the difference. raises us all. patients’ lives.
SPEAK UP AGREE ON WHO DOES WHAT ACT WITH INTEGRITY RECOGNIZE ONE ANOTHER
We say what’s on our mind – We assign clear responsibilities We always do the right thing – We honor our colleagues and
because candor makes – because effective collaboration because patients’ lives depend their efforts – because praise
us stronger. depends on clarity. on us. sparks passion.
BE DECISIVE MEASURE OUTCOMES REDUCE HEALTHCARE DISPARITIES HAVE FUN
We make choices – because We always use metrics – We strive to serve all patients – We can always make room to
time and resources are because you can’t manage because everyone should have be playful – because laughter
precious. what you can’t measure. a chance to be healthy. is good medicine, too.
2022 PFIZER FELLOWSHIP PROGRAM | 3
DIVERSITY & INCLUSION
DIVERSITY, EQUITY, AND INCLUSION
ARE CRUCIAL TO PFIZER
EQUITY RUNS THROUGH EVERYTHING WE DO
We realize that means not just attracting the best and brightest talent, but also ensuring that our colleagues
can thrive in an environment and culture where we champion diversity and inclusion every day around the
world.
It’s about who we are. We want all our colleagues to develop, grow, and succeed. We commit ourselves to
making that happen, and to sharing and celebrating our successes as we bring together people of all
backgrounds, geographies, and perspectives.
OUR INSPIRATION: AS DIVERSE AS THE PATIENTS AND COMMUNITIES WE SERVE
We are all accountable to make diversity, equity, and inclusion a part of our DNA and unlock its power to
serve patients.
For more details, visit:
careers.pfizer.com/en/diversity-inclusion
2022 PFIZER FELLOWSHIP PROGRAM | 4
INTRODUCTION TO THE PFIZER
FELLOWSHIP PROGRAM
GREETINGS FROM OUR CHIEF
MEDICAL OFFICER & HEAD OF
WORLDWIDE MEDICAL & SAFETY
I would like to thank our partner Rutgers University, and welcome everyone considering participating in
the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program.
We believe our colleagues are our greatest asset, as they work every day to advance biomedical
innovation and improve health outcomes for patients. Our purpose, defined as breakthroughs that
change patients’ lives, ensures that we place patients in the center of everything we do from research
and development, to manufacturing, to training and developing the next generation of scientific and
medical leaders.
In the following pages, you will learn more about Pfizer’s partnership with Rutgers and our efforts
to support the program, through which fellowship alumni have garnered a wide variety of leadership
opportunities at Pfizer and beyond. You will come to learn that our Pfizer colleagues are committed to
your success, providing comprehensive, real-world experience to foster the development of leadership,
as well as corporate and Pfizer-specific skills, while building a culture that optimizes the contributions
of fellows who join us.
We wish you great success in your personal and professional endeavors, and hope to work with you.
Aida Habtezion, MD, MSc
Chief Medical Officer & Head of Worldwide Medical & Safety
Pfizer Inc.
2022 PFIZER FELLOWSHIP PROGRAM | 5
INTRODUCTION TO THE PFIZER
FELLOWSHIP PROGRAM
WELCOME FROM OUR
FELLOWSHIP DIRECTOR
On behalf of Pfizer, we would like to thank you for your interest in the Rutgers Pharmaceutical Industry
Fellowship (RPIF) Program. The pharmaceutical industry is a dynamic work environment that provides
many exciting opportunities. Through this program, Pfizer offers a wide range of hands-on experiences
to equip fellows with the knowledge and network needed to launch rewarding and successful careers.
There is ample opportunity to work side by side with Pfizer colleagues dedicated to fostering the growth
and development of our fellows.
You will have the ability to connect with other postdoctoral programs across the company, as well as
over 600 pharmacists working at Pfizer in different positions across the company who are members of a
unique Pfizer pharmacy network known as the Pfizer Pharmacists Association (PPA).
Since 2005, the program has expanded to recruit 14 new fellows within the nine (out of 10) unique
two-year programs with them working across a variety of therapeutic areas and functions, including
Medical Affairs, Medical Information, Clinical Development, Risk Management, and Internal Medicine,
Field Medical Outcomes and Analytics. Over 60 fellows have completed our program, many of whom
remain with Pfizer.
Being part of our program will provide you the resources and support to help you pursue your goals
and do something exceptional. There is a dedicated leadership team in place, composed of strong
advocates for the fellows, including executive sponsors, program directors, and two co-chief fellows.
Both the leadership team and preceptors ensure that fellows develop the core capabilities to succeed,
while maintaining continued program innovation and improvement. Selecting this program also exposes
you to an invaluable professional network.
We invite you to strongly consider joining the Pfizer community, so together we can work towards the
Pfizer purpose of delivering breakthroughs that change patients’ lives. We wish you the best of luck
during the recruitment process and on the next phase of your career.
Lisa Tarasenko, BS, PharmD, MBA
Senior Medical Director, Global Medical Affairs, Internal Medicine Early Asset Lead
Fellowship Director, Pfizer/RPIF Program
2022 PFIZER FELLOWSHIP PROGRAM | 6
LEADERSHIP TEAM STRUCTURE 2021–2022
PFIZER FELLOWSHIP LEADERSHIP TEAM
F E L LO W S H I P C O - D I R E C T O R S EXECUTIVE SPONSORS
Lisa Tarasenko, PharmD, MBA
Julia Perkins Smith, MD Andrew Coop David DeMicco, PharmD Ehab Mahgoub, MD, MSc
Senior Director, IM Early Asset Lead
Global Clinical Lead, Oncology VP, NA Medical Affairs, Oncology VP, Head of GMA, Internal Medicine Head, NA Medical Affairs, I&I
PROGRAM DIRECTORS
ONCOLOGY H O S P I TA L B U S I N E S S NA MEDICAL AFFAIRS – I&I CLINICAL DEVELOPMENT
Sergio Gatoulis, PharmD, RPh
Senior Medical Director, Pfizer Oncology
CO - C H I E F F E L L O W S Sergio Gatoulis, PharmD, RPh Mary Baker, PharmD, MBA, FASPEN Arif Soonasra, PharmD Anthony Porcari, PharmD, PhD
Senior Medical Director, Senior Director, NA Medical Affairs, Hospital Sr. Medical Director, Biosimilars Clinical Program Lead, CD&O
Pfizer Oncology
RARE DISEASE NAMA/GMA – IM GMI/GMA GMI/GMA
Elpitha Soussou, PharmD, MBA
Fellow, GMA, Oncology
Alex Schepart, PharmD, MBA Lisa Tarasenko, PharmD, MBA Stacey Follman, PharmD Geri Kelsch, PharmD
Director, NA Medical Affairs, Senior Director, IM Early Asset Lead Global Content Manager (Secondment) Associate Director, Medical Information
Rare Disease
P R O G R A M C O O R D I N ATO R H R C O O R D I N AT O R
Farah Pragga, PharmD
Fellow, GMA, Internal Medicine
Lydia Douglass Nacho Magana
Exec. Admin. Assistant LT Member, Human Resources
2022 PFIZER FELLOWSHIP PROGRAM | 7
2022 PFIZER FELLOWSHIP PROGRAM | 8
OUR CURRENT FELLOWS
SECOND-YEAR FELLOWS
ONCOLOGY I N F L A M M AT I O N & I M M U N O L O G Y INTERNAL MEDICINE H O S P I TA L B U S I N E S S GMI/GMA
Caroline DiCristo, PharmD Elpitha Soussou, PharmD, MBA Alexander Agyei Marfo, Pooja Shah, PharmD, MS Nino Katchiuri, PharmD Domenick Francis, PharmD Farah Pragga, PharmD
U.S. Medical Affairs Global Medical Affairs BPharm, PharmD North America Medical Affairs Global Medical Affairs Global Medical Affairs Global Medical Affairs,
North America Medical Affairs Internal Medicine
FIRST-YEAR FELLOWS
ONCOLOGY I N F L A M M AT I O N & I M M U N O L O G Y INTERNAL MEDICINE H O S P I TA L B U S I N E S S GMI/GMA
Rebecca Michael, PharmD Kris Jaho, PharmD, RPh Michelle Segovia, PharmD Jennifer Soffing, PharmD Elizabeth Wilks, PharmD Patrick McCurry, PharmD
U.S./Global Medical Affairs Global Medical Affairs Global Medical Affairs NAMA/GMA NAMA Global Medical Information
RARE DISEASE CLINICAL DEVELOPMENT RISK MANAGEMENT
Simran Randhawa, PharmD Crystal Lee, PharmD
Global Medical Affairs Global Medical Affairs
Keeana Ross, PharmD, MBA Peter Kim, PharmD Ana Macarenco, PharmD, MPH
U.S. Medical Affairs CD&O
2022 PFIZER FELLOWSHIP PROGRAM | 9
F IR S T- YE A R F E L LOW S SECOND-Y EAR FEL LOWS
[NEW] Internal Medicine, Field Medical Outcomes and Analytics: [2 years, NY headquarters] 1 fellow
Clinical Development: [2 years, Pfizer site relevant to therapeutic area] 2 fellows
U.S./Global Medical Affairs, Oncology: [2 years, NY headquarters] 4 fellows
FELLOWSHIPS U.S. Medical Affairs, Rare Disease: [2 years, NY headquarters]
North America/Global Medical Affairs, Hospital Business Unit: [2 years, NY headquarters]
1 fellow
1 fellow
RECRUITING North America Medical Affairs, Inflammation & Immunology: [2 years, Collegeville, PA location] 2 fellows
Global Medical Affairs, Inflammation & Immunology: [2 years, NY headquarters] 1 fellow
North America/Global Medical Affairs, Internal Medicine: [2 years, NY headquarters] 1 fellow
Global Medical Information/Internal Medicine, Global Medical Affairs: [2 years, NY headquarters] 1 fellow
2022 PFIZER FELLOWSHIP PROGRAM | 10U.S. AND GLOBAL MEDICAL AFFAIRS – ONCOLOGY
FELLOWSHIP OVERVIEW
INTRODUCTION TO PFIZER
ONCOLOGY
At Pfizer, we utilize science and our global resources to bring therapies to people that extend and
significantly improve their lives. We aim to set the standard for quality, safety, and value in the discovery,
development, and manufacturing of healthcare products, including innovative medicines and vaccines.
Within the Oncology unit, we are striving to change the trajectory of cancer – we have an industry-lead-
ing portfolio of more than 24 approved, innovative cancer medicines and biosimilars across more than
30 indications, including breast, genitourinary, colorectal, blood, and lung cancers, as well as melanoma.
Every day, our Pfizer colleagues work across developed and emerging markets to advance wellness,
prevention, treatments, and cures that challenge the most feared diseases of all time.
Supporting these efforts are teams of dedicated colleagues focused on understanding the specific
needs of people living with cancer and providing support to oncology investigators, practitioners, and
caregivers. Our U.S. and Global Medical Affairs teams both play integral roles in the drug-development
continuum.
Dany Habr, MD
SVP & Chief Medical Officer
Pfizer Oncology
2022 PFIZER FELLOWSHIP PROGRAM | 11U.S. AND GLOBAL MEDICAL AFFAIRS - ONCOLOGY
FELLOWSHIP OVERVIEW
RECRUITING
RECRUITING
The purpose of this fellowship program is to provide PharmDs with the skills and experiences needed to launch a successful career in the
pharmaceutical industry through specialized training in oncology medical affairs. The Pfizer Oncology Medical Affairs Fellowship offers PharmDs
a broad overview of important areas within the industry and provides them valuable networking opportunities. Fellows will expand their clinical
knowledge by gaining exposure to a wide range of therapeutic areas and treatments within oncology that may include: breast, hematology, lung,
renal cell carcinoma, prostate, melanoma, biosimilars, and immuno-oncology. Fellows will be expected to work closely with medical directors and
provide support through active participation in the development and execution of a broad range of medical-affairs activities. For 2022, Pfizer
Oncology is recruiting to fill four two-year fellowship (from July 2022 to June 2024) positions in Medical Affairs:
• 2 Global/NAMA Breast Fellows
• 1 NAMA Hematology Fellow
• 1 NAMA Genitourinary Fellow
Develop critical interaction skills and build a network: • Provide input regarding the development of medical publications
and ensure the scientific accuracy of manuscripts
• Collaborate with cross-functional teams, including marketing,
commercial, communications, regulatory affairs, legal, health • Participate in development and review of medical slides, including
economics & outcomes research, and clinical research and training documents for field-based colleagues
development
• Offer insight to team members regarding current practices and
• Attend regional and national scientific and medical conferences potential future paradigm shifts
and report key findings
Gain experience in the operational aspects of the industry:
• Participate in a lunch-and-learn series to get to know more
about various roles through cross-functional colleagues • Plan and coordinate medical advisory board meetings
• Support collaboration with key stakeholders to develop strategy, • Research, create, and review medical response letters and dossiers
implement studies, and interpret data to ensure fair and scientifically balanced responses to medical
inquiries
• Interact with key medical opinion leaders and other healthcare
practitioners • Support appropriate dissemination of clinical trial results and
real-world evidence
Transfer knowledge and become a valued team member:
• Partner with field-based medical colleagues in supporting
• Provide medical review of promotional materials investigator-led studies, research activities, and communications
with healthcare professionals
2022 PFIZER FELLOWSHIP PROGRAM | 12U.S. AND GLOBAL MEDICAL AFFAIRS – ONCOLOGY
FELLOWSHIP OVERVIEW
MEDICAL AFFAIRS – ONCOLOGY
P R E C E P TO R S PROGRAM DIRECTOR
Caroline Hoang, PhD Yao Wang, MD Michelle Edwards, PharmD Sergio Gatoulis, PharmD, RPh
Team Lead Senior Medical Director Senior Director and Team Lead Senior Medical Director
U.S. Medical Affairs Global Medical Affairs North America Medical Affairs U.S. Medical Affairs
F E L LO W S
Caroline DiCristo, PharmD Elpitha Soussou, PharmD, MBA Rebecca Michael, PharmD
U.S./Global Medical Affairs U.S./Global Medical Affairs U.S./Global Medical Affairs
2022 PFIZER FELLOWSHIP PROGRAM | 13GLOBAL MEDICAL INFORMATION (GMI)/
GLOBAL MEDICAL AFFAIRS (GMA),
INTERNAL MEDICINE – FELLOWSHIP OVERVIEW
GLOBAL MEDICAL INFORMATION GLOBAL MEDICAL AFFAIRS, INTERNAL
S TA K E H O L D E R EXECUTIVE SPONSOR
MEDICINE
The mission of Global Medical Information is
to empower our customers to make informed The mission of Global Medical Affairs, Internal
decisions through quality interactions that Medicine, is to enhance the knowledge of our
benefit patients. medicines and the associated therapeutic ar-
eas, in which we strengthen our research ef-
We aim to strengthen Pfizer’s mission and forts and interpret emerging scientific trends,
purpose by ensuring easy-to-access and clinical data, and the competitive landscape,
easy-to-use information and knowledge that and align internal stakeholders on a balanced
significantly impacts patient care. Our product benefit-risk proposition.
expertise and customer interactions enable
us to share valuable insights with our internal Our purpose is to create, demonstrate, and
partners and to develop innovative solutions communicate the clinical value of our med-
that support the medical information needs of icines, with patients’ best interests always
our customers. coming first. We lead scientific dialogue with
the medical and scientific communities in an
Dominick Albano, PharmD, MBA accurate and fair manner about the benefits
Vice President and the risks of our medicines. This empowers
Global Medical Information prescribers and other healthcare personnel
to make informed decisions with patients and
use our medicines safely and effectively.
David DeMicco, PharmD
Vice President
Head of Global Medical Affairs,
Internal Medicine
2022 PFIZER FELLOWSHIP PROGRAM | 14GLOBAL MEDICAL INFORMATION (GMI)/ GLOBAL
MEDICAL AFFAIRS (GMA), INTERNAL MEDICINE –
FELLOWSHIP OVERVIEW
F I R S T Y E A R : G L O B A L M E D I C A L I N F O R M AT I O N *
The GMI fellow takes on the roles and responsibilities of a Medical Information Manager. This fellow will be exposed
to the foundational elements of Medical Information (MI) and have the opportunity to work in our MI community
locally, regionally, and globally. In addition, the fellow will work cross-functionally on various projects with other Pfizer
business units. Responsibilities include but are not limited to:
Understanding the medicine, the therapeutic area, Communicating to customers and stakeholders to
and the information needs of the medical community, facilitate the safe and effective use of Pfizer prescrip-
patients, and caregivers: tion products:
• Develop and leverage expertise as a subject matter • Provide balanced, scientific, and evidence-based
expert on assigned Pfizer product(s) and in answers to unsolicited medical questions from
associated therapeutic area(s) our customers
• Proactively analyze inquiry data to identify customer • Contribute to the management of product
insights and trends, and subsequently construct issues and business objectives by collaborating
and execute strategic action plans when key medical with cross-functional team members: medical
and customer issues are identified affairs, field medical, safety, regulatory affairs,
labeling, health economics & outcomes research,
Generating valued clinical and scientific responses to and legal
assist in making informed healthcare decisions:
• Participate in strategic initiatives designed to
• Perform in-depth research, analysis, and enhance the delivery of MI through digital channels
interpretation of the medical literature from both by leveraging cutting-edge technology to improve
external and internal sources internal processes and provide greater efficiency
to Pfizer MI
• Research unsolicited MI inquiries by utilizing
medical resources, clinical knowledge, and scientific • Join Pfizer in unleashing the power of partnerships
literature towards equity and making a difference by reducing
healthcare disparities
• Actively participate in the creation and maintenance
of regional and global MI scientific response *Therapy area will be determined by business
documents by ensuring that responses are need.
medically and scientifically accurate, timely, fair
and balanced, and meet customer needs
2022 PFIZER FELLOWSHIP PROGRAM | 15GLOBAL MEDICAL INFORMATION (GMI)/ GLOBAL
MEDICAL AFFAIRS (GMA), INTERNAL MEDICINE –
FELLOWSHIP OVERVIEW
SECOND YEAR: GLOBAL MEDICAL AFFAIRS
The focus of the second year of the GMI/GMA fellowship is for the fellow to acquire a firm understanding of global
medical affairs through a multitude of participatory and leadership experiences. The fellow will have the opportunity to:
Understand the medicine, therapeutic area, and • Assist in the development of medical content for
customer perspectives: congresses, symposia, speaker trainings,
and advisory boards
• Understand and interpret emerging scientific
trends, clinical data, and the competitive landscape, • Support the development of life-cycle management
and align internal stakeholders on a balanced plans to maximize clinical and patient benefits
benefit-risk proposition
Communicate the appropriate use, benefit-risk
• Partner with key thought leaders, professional balance, and clinical value of our medicines in an
societies, and patient and disease advocacy groups accurate, fair, and balanced manner:
to better understand and gain insights into areas of
unmet medical need for patients • Serve as a reliable, trusted resource for accurate,
current medical and scientific knowledge (e.g.,
Create, evaluate, and integrate clinical data and disease states, product labeling), including
content: competitive medicines, for internal and external
stakeholders and customers
• Participate in publication subcommittee meetings to
plan and implement appropriate publication • Develop communication tools that provide an
strategies and tactics for the medicine accurate, fair, and balanced perspective of our
medicines empowering prescribers and other
• Proactively collaborate on the development and healthcare personnel to make informed decisions
review of promotional materials with patients and use our medicines safely and
effectively
2022 PFIZER FELLOWSHIP PROGRAM | 16G L O B A L M E D I C A L I N F O R M AT I O N ( G M I ) / G L O B A L
MEDICAL AFFAIRS (GMA), INTERNAL MEDICINE –
FELLOWSHIP OVERVIEW
GLOBAL MEDICAL INFORMATION
S TA K E H O L D E R P R E C E P TO R P R O G R A M D I R E C TO R FELLOW
Mary Sendi, PharmD Geri Kelsch, PharmD Stacey Follman, PharmD Patrick McCurry, PharmD
Regional Lead (North America) Associate Director Global Content Manager (Secondment) Global Medical Information
Medical Information Medical Information
GLOBAL MEDICAL AFFAIRS – INTERNAL MEDICINE
P R E C E P TO R S FELLOW
Lisa Tarasenko, BS, PharmD, MBA Fady Ntanios, PhD Brian Klee, MD Farah Pragga, PharmD
Senior Medical Director, Internal Senior Medical Director, Internal Global Medical Lead Global Medical Affairs
Medicine Early Asset Lead Medicine Early Asset Lead Global Medical Affairs
Global Medical Affairs Global Medical Affairs
2022 PFIZER FELLOWSHIP PROGRAM | 17NORTH AMERICA MEDICAL AFFAIRS (NAMA)/GLOBAL MEDICAL AFFAIRS
(GMA) – INTERNAL MEDICINE FELLOWSHIP OVERVIEW
OVERVIEW OF INTERNAL MEDICINE
Pfizer’s mission is to deliver medicines that make a real difference in quality of life for patients. Our portfolio of leading medicines treats the most
prevalent challenges faced by today’s largest patient populations. We provide innovative medicines that prevent strokes, reduce blood clots,
manage chronic pain, improve glycemic control, and help people quit smoking.
Our success is driven by the talent and wide-ranging capabilities of our people, who are dedicated to addressing the greatest patient needs.
Medical Affairs is where science and healthcare meet. We are the interface between clinical development and clinical practice. The purpose
of Medical Affairs is to create, demonstrate, and effectively communicate the clinical value of our medicines, with patients’ best interests
always coming first. Our goal is to ensure that Pfizer’s medicines are used appropriately in patients to optimize outcomes and clinical value
for patients.
P R E C E P TO R S
Olga Tarasova, MD John Gillespie, MD, MBA Lisa Tarasenko, BS, PharmD, MBA
Senior Director Eliquis Lead Senior Medical Director, Internal
North America Medical Affairs North America Medical Affairs Medicine Early Asset Lead
Global Medical Affairs
F E L LO W S
Jennifer Soffing, PharmD Nino Katchiuri, PharmD
North America Medical Affairs Global Medical Affairs
2022 PFIZER FELLOWSHIP PROGRAM | 18NORTH AMERICA MEDICAL AFFAIRS (NAMA)/GLOBAL
MEDICAL AFFAIRS (GMA) - INTERNAL MEDICINE
FELLOWSHIP OVERVIEW
RECRUITING
RECRUITING
The two-year North America Medical Affairs (NAMA)/Global Medical Affairs (GMA) fellowship provides a unique opportunity to work in two exciting areas of medical affairs within
the pharmaceutical industry. The fellow will gain a broad understanding of medical affairs through both participatory and leadership experience from the perspectives of NAMA/
GMA colleagues and cross-functional team members.
• During the first year, the fellow will be based at Pfizer’s headquarters in NY and will work with the North America Medical Affairs group, the Internal Medicine business unit.
Potential therapeutic areas of focus include cardiovascular and metabolic, as well as pain and general medicine.
• In the second year, the fellow will continue to be based at Pfizer’s NY headquarters and will work with the Global Medical Affairs group, the Internal Medicine business unit.
The fellow will be afforded the opportunity to:
Understand the medicine, therapeutic area, and customer perspectives: Communicate the appropriate use, benefit-risk balance, and clinical value of our
medicines in an accurate, fair, and balanced manner:
• Understand the product/medicine and the formulation of the concept/strategy, and
how they relate to customers’ needs • Serve as a reliable trusted resource of accurate, current medical and scientific
knowledge (e.g., disease states, product labeling, other available medicines, statistics
• Interpret and understand emerging scientific trends and clinical data, as well as the interpretation, etc.) for internal and external stakeholders
competitive landscape
• Partner with important external medical and scientific leaders in collaboration with
Create, evaluate, and integrate clinical data and content: field-based medical colleagues
• Participate in publication subcommittee meetings to plan and implement • Engage with medical and scientific communities about disease state(s) and the
appropriate publication strategies and tactics in accordance with Pfizer’s policy benefits and risks of our medicines, enabling healthcare professionals to make
well informed decisions on the right medicine for the right patient at the right time
• Develop medical content for congresses, symposia, speaker trainings, and advisory
boards and participate in such activities in full compliance with Pfizer’s policy
• Enhance the understanding of our medicines through additional clinical trials and
real-world data from development and throughout the product life cycle
• Proactively collaborate on the development and review of promotional materials
2022 PFIZER FELLOWSHIP PROGRAM | 19NORTH AMERICA MEDICAL AFFAIRS (NAMA)
G L O B A L M E D I C A L A F F A I R S ( G M A ) – H O S P I TA L
BUSINESS FELLOWSHIP OVERVIEW
OVERVIEW OF HOSPITAL BUSINESS
Pfizer’s mission is to deliver medicines that make a real Our success is driven by the talent and wide-ranging
difference in quality of life for patients. Pfizer established capabilities of our people, who are dedicated to
the Hospital Business unit (HBU) in 2019 to ensure vital addressing the greatest patient needs.
medicines are delivered to patients, providers, and cus-
tomers where they are needed most. The unit is the third Medical Affairs is where science and healthcare meet. We
largest within the Biopharmaceuticals Group, which is the are the interface between clinical development and clin-
commercial organization of Pfizer, and encompasses over ical practice. The purpose of Medical Affairs is to create,
700 medicines in three broad areas: demonstrate, and effectively communicate the clinical val-
ue of our medicines, with patients’ best interests always
• Anti-infectives (e.g., Zavicefta, Zinforo, Cresemba) coming first. Our goal is to ensure that Pfizer’s medicines
are used appropriately in patients to optimize outcomes
• Sterile injectables (>700 injectable products, mostly and clinical value for patients.
generic)
Throughout both years, the fellow will have the opportu-
• Hospital products (e.g., immunoglobulins [Panzyga, nity to interact with a broad network of colleagues out-
Cutaquig], hemostatics [Gel-Flow, Thrombin-JMI], side of their location (Field Medical, Independent Medical
Monoferric, Fragmin, chemotherapeutics) Education, Investigator-Initiated Research, Health Eco-
nomics & Outcomes Research, Regulatory, Commercial,
The Hospital Business unit works across a range of sites and Legal), as well as Medical Affairs colleagues outside
of care such as: hospitals, infusion clinics, and long-term the U.S.
care facilities. Therapeutic areas of focus include critical
care, surgery, infectious diseases, and overall hospital
care.
2022 PFIZER FELLOWSHIP PROGRAM | 20NORTH AMERICA MEDICAL AFFAIRS (NAMA)/GLOBAL
MEDICAL AFFAIRS (GMA) - HOSPITAL BUSINESS
FELLOWSHIP OVERVIEW
RECRUITING
RECRUITING
The two-year North America Medical Affairs (NAMA)/Global Medical Affairs (GMA) fellowship provides a unique opportunity to work in two exciting areas of medical affairs within
the pharmaceutical industry. The fellow will gain a broad understanding of medical affairs through both participatory and leadership experience from the perspectives of NAMA/
GMA colleagues and cross-functional team members.
• During the first year, the fellow will be based at Pfizer’s headquarters in NY or the office in Collegeville, PA, and will primarily work with the North America Medical
Affairs group, the Hospital Business unit. Potential therapeutic areas of focus include cardiovascular and metabolic, as well as pain and general medicine.
• In the second year, the fellow will continue to be based at Pfizer’s NY headquarters or the office in Collegeville, PA, and will primarily work with the Global Medical
Affairs group, the Hospital Business unit.
The fellow will be afforded the opportunity to:
Understand the medicine, therapeutic area, and Create, evaluate, and integrate clinical data and Communicate the appropriate use, benefit-risk
customer perspectives: content: balance, and clinical value of our medicines in an
accurate, fair, and balanced manner:
• Gain knowledge on the product/medicine (often • Participate in publication subcommittee
with a device component) and the formulation of meetings to plan and implement appropriate • Serve as a reliable trusted resource of accurate,
the concept/strategy, and how they relate to publication strategies and tactics in accordance current medical and scientific knowledge (e.g.,
customers’ need with Pfizer’s policy disease states, product labeling, other available
medicines, statistics interpretation, etc.) for
• Interpret and understand emerging scientific • Develop medical content for congresses, internal and external stakeholders
trends and clinical data, as well as the symposia, speaker trainings, and advisory
competitive landscape boards and participate in such activities in full • Partner with important external medical and
compliance with Pfizer’s policy scientific leaders in collaboration with field-based
• Conduct ongoing assessment of the benefit-risk medical colleagues
balance of the existing portfolio of medicine(s), • Enhance the understanding of our medicines
as well as for development of new ones, based through additional clinical trials and real-world • Engage with medical and scientific communities
on new data, when available data from development and throughout the about disease state(s) and the benefits and risks
product life cycle of our medicines, enabling healthcare
• Focus on customer-centric innovation (CCI) professionals to make well informed decisions
intended to generate new ideas and potential • Proactively collaborate on the development and on the right medicine for the right patient at
value-added opportunities to benefit patient review of promotional materials the right time
care
• Offer insight to team members regarding • Partner with field-based medical colleagues in
current practices and potential future paradigm supporting investigator-led studies, research
shifts activities, and communications with healthcare
professionals
2022 PFIZER FELLOWSHIP PROGRAM | 21NORTH AMERICA MEDICAL AFFAIRS (NAMA)/
G L O B A L M E D I C A L A F F A I R S ( G M A ) – H O S P I TA L
BUSINESS FELLOWSHIP OVERVIEW
NORTH AMERICA MEDICAL AFFAIRS
S TA K E H O L D E R P R E C E P TO R FELLOW
Edward Power, PhD, MBA, GFMD Mary Baker, PharmD, MBA, FASPEN Elizabeth Wilks, PharmD
Vice President Senior Director, Sterile Injectables North America Medical Affairs
North America Medical Affairs
GLOBAL MEDICAL AFFAIRS
P R E C E P TO R S FELLOW
Judith Hey-Hadavi, DDS, MD, MSc Jay Purdy, MD, PhD Bruce Altevogt, PhD Domenick Francis, PharmD
Global Medical Lead, Sterile Injectables Global Medical Lead, Anti-Infectives External Medical Engagement Lead Global Medical Affairs
2022 PFIZER FELLOWSHIP PROGRAM | 22NORTH AMERICA MEDICAL AFFAIRS
(NAMA)/GLOBAL MEDICAL AFFAIRS
(GMA) - INFLAMMATION & IMMUNOLOGY
FELLOWSHIP OVERVIEW
For decades, healthcare professionals have relied on traditional medicines for inflammatory and
EXECUTIVE SPONSOR
immunological diseases. Through the discovery and development of novel therapies, science has
continued to advance, with patients’ best interests, as well as the efficacy and safety of medications,
always coming first.
Our mission is to deliver breakthroughs that enable freedom from day-to-day suffering for people
with chronic inflammatory diseases, which can be debilitating and distressing – significantly affect-
ing what they can do.
The goal of Pfizer Inflammation & Immunology (I&I) is to transform the treatment of chronic inflam-
matory and autoimmune diseases. At I&I Medical Affairs, we provide our customers with accurate and
clinically relevant information about our medicines that help them make the right treatment decisions
through data generation and dissemination and peer-to-peer interactions. Our colleagues lead with
integrity and by example on medical professionalism and scientific excellence; we meet our ultimate
purpose to ensure that all appropriate patients can safely and effectively benefit from our current and
future medicines.
Ehab Mahgoub, MD, MSc
Head of I&I
North America Medical Affairs
2022 PFIZER FELLOWSHIP PROGRAM | 23NORTH AMERICA MEDICAL AFFAIRS (NAMA)/GLOBAL MEDICAL AFFAIRS
RECRUITING
( G M A ) – I N F L A M M AT I O N & I M M U N O L O G Y F E L L O W S H I P O V E R V I E W
The purpose of Medical Affairs is to create, demonstrate, and effectively communicate the clinical value of our medicines, with patients’ best interests always
coming first.
Our mission is to enhance the knowledge of our medicines and the associated therapeutic areas, in which we strengthen our research efforts and interpret
emerging scientific trends, clinical data, and the competitive landscape, and align internal stakeholders on a balanced benefit-risk proposition. We lead
scientific dialogue with the medical and scientific communities in an accurate and fair manner about the benefits and the risks of our medicines. This empowers
prescribers and other healthcare personnel to make informed decisions with patients and use our medicines safely and effectively. Our purpose makes sure that
patients remain at the center of all we do at Pfizer.
Develop therapy area expertise: • Partner with key thought leaders, professional societies, and patient and
disease advocacy groups to better understand and gain insights into areas
• Develop and leverage expertise as a subject matter expert of unmet medical need for patients
on assigned Pfizer product(s) and in associated therapeutic area(s)
• Participate in the publication of scientific abstracts and manuscripts
• Understand and interpret emerging scientific trends,
clinical data, and the competitive landscape, and align Build technical and professional skills:
internal stakeholders on a balanced benefit-risk proposition
• Provide guidance on commercial projects, including strategy, material
• Serve as a reliable, trusted resource for accurate, current medical and review, and training
scientific knowledge (e.g., disease states, product label), including
competitive medicines, for internal and external stakeholders • Assist in the coordination and planning of pivotal medical meetings
Interact with the scientific community: • Assist in the development of medical content for meetings, symposia,
and speaker trainings
• Attend scientific and medical conferences and report on key findings
2022 PFIZER FELLOWSHIP PROGRAM | 24NORTH AMERICA MEDICAL AFFAIRS (NAMA)/GLOBAL MEDICAL AFFAIRS
( G M A ) – I N F L A M M AT I O N & I M M U N O L O G Y F E L L O W S H I P O V E R V I E W
NORTH AMERICA MEDICAL AFFAIRS
RECRUITING
P R E C E P TO R S FELLOWS
Arif Soonasra, PharmD Liza Takiya, PharmD, BCPS Alexander Agyei Marfo, BPharm, PharmD Pooja Shah, PharmD, MS
Senior Medical Director Senior Medical Director North America Medical Affairs – North America Medical Affairs –
North America Medical Affairs North America Medical Affairs Dermatology Rheumatology/Gastroenterology/Biosimilars
GLOBAL MEDICAL AFFAIRS
RECRUITING
PRECEPTORS FELLOWS
Amy Cha, PharmD Xiang Guo, PharmD Kris Jaho, PharmD, RPh Simran Randhawa, PharmD Crystal Lee, PharmD Michelle Segovia, PharmD
Senior Medical Director Medical Director, Xeljanz Global Medical Affairs – Global Medical Affairs – Global Medical Affairs – Global Medical Affairs –
Medical Research Head Global Medical Affairs Dermatology Dermatology Dermatology Gastroenterology
Global Medical Affairs
2022 PFIZER FELLOWSHIP PROGRAM | 25U.S. MEDICAL AFFAIRS – RARE DISEASE
FELLOWSHIP OVERVIEW
OVERVIEW OF RARE DISEASE
S TA K E H O L D E R
Rare diseases are among the most serious of all illnesses and impact millions of patients worldwide,
representing an opportunity to utilize our knowledge and expertise to help make a significant impact
in addressing unmet medical needs. The treatment options are few, and with both quality of life and
longevity relying on new breakthroughs, our shared urgency must be kept front and center.
With more than two decades of experience, Pfizer Rare Disease is a dedicated research unit focusing on
rare diseases, and has a global portfolio of more than 20 medicines approved worldwide that treat rare
diseases in the areas of cardiology, hematology, neurology, and endocrinology. Pfizer is leading bold
approaches and pioneering collaborations to make a meaningful difference in the lives of those affected
by rare disease.
We have worked alongside the rare disease community for decades with an unmatched passion for
delivering life-changing medicines through scientific innovation. Every advance has moved us forward
to bring new medicines to the rare-disease patients who need them. Pfizer Rare Disease combines
pioneering science with a deep understanding of how diseases work to deliver innovative treatments.
At Pfizer Rare Disease, we passionately dedicate our resources, expertise, and global reach to bring-
ing innovative medicines to rare disease patients and their families.
Younos Abdulsattar, PharmD, BCPS, MBA
Vice President
North America Medical Lead
Rare Disease
2022 PFIZER FELLOWSHIP PROGRAM | 26U.S. MEDICAL AFFAIRS - RARE DISEASE
FELLOWSHIP OVERVIEW
RECRUITING
The goals of this fellowship are to provide the fellow with the skills and experience needed to be successful in a career
within the pharmaceutical industry, with a focus in Medical Affairs. The fellow will also work with various cross-func-
tional teams, such as Medical Information, Marketing, Patient & Health Impact, Sales, Regulatory, and Legal, and will
be provided with broad opportunities to partner and/or lead different Medical Affairs projects across the Rare Disease
portfolio, including hematology inline and pipeline assets.
Understand the data and build strong communication Generate data and garner insights:
skills:
• Understand and participate in the publication
• Support medical content review in developing planning process for Rare Disease products
promotional material through review committee (RC)
in partnership with cross-functional colleagues, such • Understand and participate in preparing medical
as regulatory, legal, and marketing strategies and tactics
• Support the development of internal training • Plan and execute key competitive-intelligence
resources for cross-functional colleagues, including activities, including national congresses, with
sales training cross-functional colleagues
• Support the development and approval of resources U.S. Medical Affairs – Rare Disease Fellowship
for field-medical colleagues through medical review Deliverables:
committee (MRC)
The fellow will have a portfolio of real-life projects/materi-
• Partner with medical-information colleagues to als completed at the end of the fellowship as evidence of
provide expert input to scientific responses developed skill sets, including:
Engage with scientific community and patients: • One or more advisory boards
• RC and MRC support
• Involve in data generation and communication • Congress support
activities (e.g., ISR [investigator-sponsored research], • Publication planning
Phase IV trials, real-world evidence, etc.) • Data generation & communication
• Training support
• Understand and participate in patient advocacy • Operating plan & budget
initiatives
• Support and participate in the planning and execution
of advisory boards to gain insights from key thought
leaders
2022 PFIZER FELLOWSHIP PROGRAM | 27U.S. MEDICAL AFFAIRS – RARE DISEASE
FELLOWSHIP OVERVIEW
U.S. MEDICAL AFFAIRS – RARE DISEASE
P R E C E P TO R S
Priya Patel, PharmD Patrick Fogarty Cosimo Costa, PharmD, RPh Terry Anderson, PhD
Medical Director, Hemophilia Senior Medical Director, Hemophilia Senior Field Medical Director, Hemophilia Senior Field Medical Director, Hemophilia
U.S. Medical Affairs U.S. Medical Affairs U.S. Medical Affairs U.S. Medical Affairs
F E L LO W
Keeana Ross, PharmD, MBA
U.S. Medical Affairs
2022 PFIZER FELLOWSHIP PROGRAM | 28CLINICAL DEVELOPMENT
S TA K E H O L D E R
FELLOWSHIP OVERVIEW
David Scholfield, MBBS, BSc
Head of Clinical Development
& Operations
RECRUITING
PRECEPTOR
This two-year Clinical Development Fellowship will provide clinician training
and in-depth exposure to late-phase clinical development with hands-on
experience in key elements of the planning, executing, and reporting of clinical
trial results.
The fellow will develop skills as a clinician and work with cross-functional
team members to advance clinical programs toward regulatory approvals. Dorothy Fan, PharmD, RPh
Senior Manager
As opportunities arise, the fellow may have the chance to cover colleagues in
Clinical Development & Operations
other functional areas to help broaden the fellow’s overall clinical development
experience. The fellow will develop skills in:
PROGRAM DIRECTOR
Strategy:
• Develop efficient protocols which maximize operational efficiency, trial
quality, and participant/site engagement
• Provide clinical insight to ensure the safety of clinical trial participants, in
addition to data quality
Anthony Porcari, PharmD, PhD
• Plan and contribute to internal- and external-facing documents that Clinical Program Lead
Clinical Development & Operations
support conduct of clinical trials and regulatory requirements
Execution:
FELLOW
• Execute clinical protocols in accordance with established quality standards,
such as Good Clinical Practice (GCP), health authority regulations/
guidelines, and organizational standard operating procedures (SOPs)
• Regularly oversee data quality
• Ensure the safety of trial participants Peter Kim, PharmD
Clinical Development & Operations
Reporting:
• Support clinical study reports
• Develop safety narratives
• Support submission documents to regulatory authorities
2022 PFIZER FELLOWSHIP PROGRAM | 29RISK MANAGEMENT CENTER OF EXCELLENCE/U.S.
FOOD AND DRUG ADMINISTRATION (RMCOE/FDA) -
RISK MANAGEMENT FELLOWSHIP OVERVIEW
NOT RECRUITING
Purpose of the Risk Management Center of Excellence/U.S. Food and experience will provide the fellow an opportunity to be on the forefront
Drug Administration (RMCoE/FDA) – Risk Management Fellowship of a critical component of drug and biologic life-cycle management.
Additionally, the fellow will learn a broad perspective on global risk
The RMCoE fellowship will be a unique program designed to provide management in the industry and the U.S.-based approach within the
experience in U.S and global drug and biologic risk management. The FDA. This will enable the fellow to become an emerging leader in risk
fellowship will include industry- and regulatory-based experiences, management.
which will diversify the program and will position the fellow to be on the
forefront of risk management science, preparing them for a career in Pfizer Risk Management Center of Excellence Vision
the pharmaceutical industry, or with a regulatory authority.
We strive to be the industry’s premier risk-management organization
This fellowship is the first of its kind to provide a fellow with industry and delivering innovative and strategic risk-management excellence,
FDA experience specific to drug and biologic risk management. As risk regulatory compliance, and operational efficiency to provide healthcare
management policy and approach continue to rapidly evolve, this providers and patients with access to Pfizer’s portfolio of drug products.
P R E C E P TO R S FELLOW
Reema Mehta, PharmD, MPH Jamie Wilkins, PharmD Gita Toyserkani, PharmD, MBA Cynthia LaCivita, PharmD Ana Macarenco, PharmD, MPH
Head of Risk Management Director, Risk Management Associate Director, Division of Mitigation Director, Division of Risk Management Risk Management Center of Excellence
Center of Excellence Product Lead Assessment and Medication Error Surveillance CDER/OSE/OMEPRM
Pfizer Pfizer CDER/OSE/OMEPRM U.S. FDA
U.S. FDA
*As this fellowship includes a component at the U.S. FDA, U.S. citizenship is required.
2022 PFIZER FELLOWSHIP PROGRAM | 30RISK MANAGEMENT CENTER OF EXCELLENCE/U.S.
FOOD AND DRUG ADMINISTRATION (RMCOE/FDA) -
RISK MANAGEMENT FELLOWSHIP OVERVIEW
NOT RECRUITING
The two-year program will begin with global experience for the fellow, which is the industry-based pharmaceutical risk management, and then transi-
tion into the U.S. FDA during the second year, including U.S. risk management policy and operations from a regulatory perspective. The fellow will gain
a broad understanding of risk management approaches and methods focused on drugs and biologics.
• During the first year, the fellow will be based at the Pfizer office in Peapack, NJ, and will work with the Pfizer Risk Management Center
of Excellence (RMCoE) team that provides risk management strategy and operational support across Pfizer’s entire portfolio.
• During the second year, the fellow will be based at the U.S. Food and Drug Administration office in White Oak, MD: the Office of Surveillance
and Epidemiology (OSE), Office of Medication Error Prevention and Risk Management (OMEPRM), Division of Mitigation Assessment and
Medication Error Surveillance (DMAMES).
The fellow will be afforded the opportunity to:
Understand the strategy and tools for risk management: Develop understanding of regulatory processes and requirements:
• Understand pre- (Phase III) and post-marketing (Phase IV) approaches • Gain experience in global health authority’s requirements (e.g., the
to risk management strategy for drugs and biologics U.S., the E.U., Japan) with respect to risk management
• Understand risk-management tools (e.g., labeling, educational • Gain experience in drug/biologic application review
programs, controlled access programs, post-approval safety studies) from industry and regulatory perspectives
available to assess or mitigate risks in drugs and biologic products
• Develop expertise in the development of written risk-management
• Apply various risk-management frameworks (e.g., benefit-risk tools, including U.S. REMS and E.U. RMPs
framework, RE-AIM) to developing risk mitigation strategies
Communicate to any audience and work in a team:
• Develop a baseline understanding of signal evaluation
• Develop skills in presentation design and delivery for various
• Further build knowledge in risk management science through social audiences
and behavioral science perspectives, program planning and
evaluation, and behavioral assessments • Collaborate within a team setting to develop a holistic risk-
management approach on a drug or biologic product
2022 PFIZER FELLOWSHIP PROGRAM | 31INTERNAL MEDICINE, FIELD
MEDICAL OUTCOMES AND
ANALYTICS (IM, MEDICAL O&A)
FELLOWSHIP OVERVIEW
NEW FELLOWSHIP
Internal Medicine, Field Medical Outcomes and Analytics Organization
Credentials of the current team: PharmDs, BS pharmacists with MSs or
PhDs, MPHs, MBAs, DrPHs, and many board-certified with 10 to 12 years
of experience
Mission: The Internal Medicine, Field Medical Outcomes and
Analytics (IM, Medical O&A) organization utilizes medical evidence,
pharmacoeconomics, outcomes-based analyses, and our healthcare and
clinical expertise by focusing on:
Patient access to medication by:
• Enabling informed customers’ formulary decision-making
• Ensuring appropriate access to Pfizer medicines & products
for patients
Improving the quality of patient care by:
• Impacting population health at a system or organization level
• Improving patient education, engagement, and adherence
Purpose of the Two-year Internal Medicine, Field Medical Outcomes
and Analytics (IM, Medical O&A) Fellowship
• To offer the fellow a unique experience in the pharmaceutical industry,
which includes field-based and headquarters-based projects focused
on improving the quality of patient care by impacting population
health at a system level, providing patient education, and improving
adherence and engagement in the management of diseases that
Pfizer is interested in.
• This fellowship is designed to provide customized and practical
hands-on learning opportunities in both headquarters-based and
field-medical roles to enable the fellow to prepare for a strong career
in the pharmaceutical industry.
2022 PFIZER FELLOWSHIP PROGRAM | 32INTERNAL MEDICINE, FIELD MEDICAL OUTCOMES
AND ANALYTICS (IM, MEDICAL O&A)
FELLOWSHIP OVERVIEW
NEW FELLOWSHIP
YEAR ONE – ORGANIZATIONAL TRAINING AND HEADQUARTERS YEAR TWO – FIELD MEDICAL OUTCOMES SPECIALIST EXPERIENCE
EXPERIENCE
The fellow will partner with a field-based IM, Medical O&A colleague
Following the training period, the fellow will rotate with the IM, to collaborate, communicate, and interact with organized healthcare
Medical O&A Therapeutic Area Leads, who are the single point customers on:
of contact for the MOS organization and HQ-based medical and
commercial teams. The fellow will assist with: • Patient care improvement projects and initiatives
• Development and execution of IM, Medical O&A strategic and tactical • Evidence-based disease management and population-health
plans, ensuring alignment with the brand teams and integration into initiatives
the broader medical plan
• Real world data analytics, assessments and reporting
• Management of the brand’s medical budget for advanced customer
and vendor engagements to support medical strategies • Delivering clinical content to formulary decision-makers
• Development of resources for scaling up operations as a result of • Managing the local market medical needs, while working with other
advanced medical engagements field medical and commercial colleagues
• Early engagement with pipeline products, assistance with launch PROGRAM DIRECTOR PRECEPTOR
planning and tool development A N D P R E C E P TO R
• Analytics utilizing Pfizer-licensed databases and real-world evidence
(RWE) generation through involvement with advanced medical
engagements
Marcia Wright, PharmD Walter McClain, PharmD, BCPS, MBA
Senior Director Senior Director
Team Lead, Therapeutic Area and Team Lead, Northeast Region
National Key Accounts Internal Medicine, Field Medical Outcomes
Internal Medicine, Field Medical Outcomes and Analytics
and Analytics
2022 PFIZER FELLOWSHIP PROGRAM | 33ALUMNI SPOTLIGHT
The two-year U.S. Medical Affairs The Pfizer fellowship program The Pfizer fellowship program
– Rare Disease fellowship at Pfizer was a great opportunity for me provided me with the opportunity
provided me with an excellent to truly understand the impact to learn and develop the skills
platform for launching my career pharmacists can have in the necessary to have a successful
in the pharmaceutical industry. As pharmaceutical industry. I was start to my career. I had the
a fellow, I was fortunate to have involved in various fields of opportunity to work on several
had a strong group of preceptors, medical affairs and was viewed key projects across Medical
mentors, and colleagues who as an integral part of the team. I Affairs that allowed me to
ensured that I received a well- was able to direct my fellowship in gain the knowledge, skills, and
rounded experience within the direction that would be best confidence needed to cultivate
Medical Affairs. I was immersed for my growth and professional my independence and leadership.
in a variety of opportunities, all of career with the support of my Additionally, the network and
which were met with encouraging preceptor and team. Pfizer’s mentorship I developed are what I
support, acknowledgement, and guidance. I am honored to have leadership team was open to meeting with us in intimate settings will take with me throughout the rest of my career. I feel very proud
been a part of the Pfizer-Rutgers fellowship program! and allowed me to expand my professional circle, as well as gain and privileged to have graduated from this program, and would
valuable wisdom from experts within the field. highly recommend it to anyone interested in a career within the
Arianna Burton, PharmD pharmaceutical industry.
Senior Manager David Giang, PharmD
U.S. Medical Affairs – Rare Disease Global Medical Information Scientist Juan Razo, PharmD
Pfizer Oncology Senior Manager, Prostate Cancer
Merck North America Medical Affairs – Oncology
Pfizer
The Pfizer-Rutgers fellowship The Pfizer/RPIF fellowship My fellowship experience at
program is a true testament program has built a strong Pfizer was unique in that I
to Pfizer’s core values of foundation for the start of my was given the opportunity to
excellence, equity, courage, career within global medical support both a marketed and
and joy. The program offers affairs. My mentors and pipeline product from a global
innumerable learning and preceptors have provided me position. Aside from the prospect
leadership experiences, which with a multitude of unique of advanced learning, I was
created a strong foundational experiences that allowed me to exposed to multiple areas under
understanding of both medical lead and manage projects, work the medical-affairs umbrella,
information and medical affairs cross-functionally, and create which ultimately led to my next
for me. I began cultivating a new initiatives to benefit the career move. A pivotal part of
skill set that I will continuously wider I&I team. I am grateful the fellowship is engaging with
build upon. I am grateful to have to be continuously inspired by other fellows across the various
graduated from this program and learned from amazing my colleagues. Additionally, I am fortunate to have made lifelong business units. That engagement really fostered my networking and
individuals that have dedicated their time to my personal and friends through being a part of the Pfizer-Rutgers fellowship. professional development. Furthermore, Pfizer has a large network
professional growth. Learning, building relationships, and growing in my career as a of pharmacists that have successfully led teams and serve as a
Pfizer fellow have truly prepared me for my current job and will wealth of knowledge and support. I am thankful for the opportunity
Christine Joseph, PharmD contribute to my advancement in future endeavors. to have completed my fellowship at Pfizer.
Senior Manager
Women’s Health Portfolio Helen Tran, PharmD Sarah Ofori, PharmD, RPh, MBA
Pfizer Senior Manager Assistant Scientific Director
Global Medical Affairs – I&I U.S. Medical Affairs – Dermatology
Pfizer AbbVie
2022 PFIZER FELLOWSHIP PROGRAM | 34You can also read
